JP2017507966A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017507966A5 JP2017507966A5 JP2016556842A JP2016556842A JP2017507966A5 JP 2017507966 A5 JP2017507966 A5 JP 2017507966A5 JP 2016556842 A JP2016556842 A JP 2016556842A JP 2016556842 A JP2016556842 A JP 2016556842A JP 2017507966 A5 JP2017507966 A5 JP 2017507966A5
- Authority
- JP
- Japan
- Prior art keywords
- ondansetron
- solid oral
- amount
- dosage form
- seal coat
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- FELGMEQIXOGIFQ-CYBMUJFWSA-N (3r)-9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1h-carbazol-4-one Chemical compound CC1=NC=CN1C[C@@H]1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-CYBMUJFWSA-N 0.000 claims 26
- 229960005343 ondansetron Drugs 0.000 claims 25
- 239000007787 solid Substances 0.000 claims 20
- 238000009472 formulation Methods 0.000 claims 9
- 239000000203 mixture Substances 0.000 claims 9
- 239000006186 oral dosage form Substances 0.000 claims 7
- 239000011159 matrix material Substances 0.000 claims 5
- 206010012735 Diarrhoea Diseases 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims 3
- 230000036470 plasma concentration Effects 0.000 claims 3
- 229920000831 ionic polymer Polymers 0.000 claims 2
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 2
- 208000007882 Gastritis Diseases 0.000 claims 1
- 208000005577 Gastroenteritis Diseases 0.000 claims 1
- 206010028813 Nausea Diseases 0.000 claims 1
- 206010047700 Vomiting Diseases 0.000 claims 1
- 208000012873 acute gastroenteritis Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000008693 nausea Effects 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 230000008673 vomiting Effects 0.000 claims 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461951074P | 2014-03-11 | 2014-03-11 | |
| US201461951092P | 2014-03-11 | 2014-03-11 | |
| US201461951112P | 2014-03-11 | 2014-03-11 | |
| US61/951,092 | 2014-03-11 | ||
| US61/951,112 | 2014-03-11 | ||
| US61/951,074 | 2014-03-11 | ||
| US201462040136P | 2014-08-21 | 2014-08-21 | |
| US62/040,136 | 2014-08-21 | ||
| PCT/IB2015/000997 WO2015136377A2 (en) | 2014-03-11 | 2015-03-11 | Ondansetron extended release solid dosage forms for treating either nausea, vomiting or diarrhea symptoms |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017507966A JP2017507966A (ja) | 2017-03-23 |
| JP2017507966A5 true JP2017507966A5 (enExample) | 2018-04-19 |
| JP6461186B2 JP6461186B2 (ja) | 2019-01-30 |
Family
ID=54067752
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016556842A Active JP6461186B2 (ja) | 2014-03-11 | 2015-03-11 | 悪心、嘔吐または下痢の症状を処置するためのオンダンセトロン徐放固形製剤 |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US9675588B2 (enExample) |
| EP (1) | EP3116500B1 (enExample) |
| JP (1) | JP6461186B2 (enExample) |
| KR (1) | KR20160132057A (enExample) |
| CN (1) | CN106456611B (enExample) |
| AU (1) | AU2015228545B2 (enExample) |
| BR (1) | BR112016020877B1 (enExample) |
| CA (1) | CA2941829C (enExample) |
| CL (1) | CL2016002251A1 (enExample) |
| IL (1) | IL247698B (enExample) |
| MX (1) | MX373002B (enExample) |
| PH (1) | PH12016501756B1 (enExample) |
| RU (1) | RU2706708C2 (enExample) |
| SG (1) | SG11201607511WA (enExample) |
| UA (1) | UA121209C2 (enExample) |
| WO (1) | WO2015136377A2 (enExample) |
| ZA (1) | ZA201606276B (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3302442B1 (en) | 2015-06-03 | 2024-10-16 | Triastek, Inc. | Dosage forms and use thereof |
| AU2018212273B2 (en) | 2017-01-26 | 2023-12-21 | Triastek, Inc. | Dosage forms of controlled release at specific gastrointestinal sites |
| JP7315383B2 (ja) * | 2019-06-27 | 2023-07-26 | 株式会社Ｓｃｒｅｅｎホールディングス | インクジェット用水性組成物及び固体製剤 |
| WO2023102491A1 (en) * | 2021-12-01 | 2023-06-08 | Invea Therapeutics, Inc. | Methods for treating gastrointestinal inflammatory disease |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4720353A (en) | 1987-04-14 | 1988-01-19 | Richardson-Vicks Inc. | Stable pharmaceutical w/o emulsion composition |
| US5419917A (en) * | 1994-02-14 | 1995-05-30 | Andrx Pharmaceuticals, Inc. | Controlled release hydrogel formulation |
| BE1011045A3 (fr) | 1997-03-14 | 1999-04-06 | Ucb Sa | Compositions pharmaceutiques pour la liberation controlee de substances actives. |
| US6090411A (en) | 1998-03-09 | 2000-07-18 | Temple University | Monolithic tablet for controlled drug release |
| US6733789B1 (en) | 1999-01-21 | 2004-05-11 | Biovail Laboratories, Inc. | Multiparticulate bisoprolol formulation |
| AU2084801A (en) | 1999-12-09 | 2001-06-18 | Alza Corporation | Antiviral medication |
| WO2003024427A1 (en) | 1999-12-20 | 2003-03-27 | Temple University Of The Commonwealth System Of Higher Education | Tableted oral extended release dosage form |
| US6936275B2 (en) | 1999-12-20 | 2005-08-30 | Scolr, Inc. | Amino acid modulated extended release dosage form |
| US20020044962A1 (en) | 2000-06-06 | 2002-04-18 | Cherukuri S. Rao | Encapsulation products for controlled or extended release |
| US6500457B1 (en) | 2000-08-14 | 2002-12-31 | Peirce Management, Llc | Oral pharmaceutical dosage forms for pulsatile delivery of an antiarrhythmic agent |
| US20020172712A1 (en) | 2001-03-19 | 2002-11-21 | Alan Drizen | Antiemetic, anti-motion sustained release drug delivery system |
| GB0119012D0 (en) | 2001-08-03 | 2001-09-26 | Strakan Group Plc | Transdermal delivery of drugs |
| US20050131045A1 (en) | 2002-04-30 | 2005-06-16 | Judith Aronhime | Novel crystal forms of ondansetron, processes for their preparation, pharmaceutical, compositions containing the novel forms and methods for treating nausea using them |
| US7704527B2 (en) | 2002-10-25 | 2010-04-27 | Collegium Pharmaceutical, Inc. | Modified release compositions of milnacipran |
| ES2285407T3 (es) * | 2003-01-13 | 2007-11-16 | Dynogen Pharmaceuticals Inc. | Metodo para el tratamiento de nauseas, vomitos, arcadas o cualquiera de sus combinaciones. |
| JP4674162B2 (ja) * | 2003-11-14 | 2011-04-20 | 千寿製薬株式会社 | アミノグリコシド系抗生物質およびブロムフェナクを含有する水溶液製剤 |
| JP2008524332A (ja) * | 2004-12-20 | 2008-07-10 | コレジウム ファーマシューティカル， インク． | 睡眠傷害のための医薬組成物 |
| EP1970055B1 (en) | 2005-12-29 | 2010-11-24 | Osmotica Kereskedelmi És Szolgáltató Kft | Multi-layered tablet with triple release combination |
| JP5433236B2 (ja) * | 2006-01-27 | 2014-03-05 | アプタリス ファーマテック，インコーポレイテッド | 弱塩基性選択性セロトニン５−ｈｔ３遮断剤および有機酸を含む薬物送達系 |
| US20070190141A1 (en) | 2006-02-16 | 2007-08-16 | Aaron Dely | Extended release opiate composition |
| US20080004260A1 (en) | 2006-06-29 | 2008-01-03 | Transcept Pharmaceuticals, Inc. | Compositions of 5-HT3 antagonists and dopamine D2 antagonists for treatment of dopamine-associated chronic conditions |
| CA2661561C (en) * | 2006-08-18 | 2013-12-24 | Evonik Operations Gmbh | Pharmaceutical composition with controlled active ingredient delivery for active ingredients with good solubility in water |
| CN100584319C (zh) * | 2006-10-16 | 2010-01-27 | 北京科信必成医药科技发展有限公司 | 群孔释放渗透泵控释片及其制备方法 |
| MX2009004439A (es) | 2006-10-25 | 2009-05-11 | Mcneil Ppc Inc | Composicion de ibuprofeno. |
| GB0624087D0 (en) | 2006-12-01 | 2007-01-10 | Selamine Ltd | Ramipril combination salt |
| CN101568351B (zh) | 2006-12-22 | 2012-05-30 | 3M创新有限公司 | 控制释放的组合物和方法 |
| WO2009118763A1 (en) * | 2008-03-28 | 2009-10-01 | Panacea Biotec Limited | Multilayered pharmaceutical compositions and processes thereof |
| US20100196291A1 (en) | 2009-01-30 | 2010-08-05 | Laurence Halimi | Personal care sunscreen compositions having reduced eye irritation |
| EP2403487A2 (en) | 2009-03-04 | 2012-01-11 | Fdc Limited | Oral controlled release dosage forms for water soluble drugs |
| US20110003005A1 (en) | 2009-07-06 | 2011-01-06 | Gopi Venkatesh | Methods of Treating PDNV and PONV with Extended Release Ondansetron Compositions |
| US20110108058A1 (en) * | 2009-11-11 | 2011-05-12 | Axcelis Technologies, Inc. | Method and apparatus for cleaning residue from an ion source component |
| CA2784587A1 (en) * | 2009-12-28 | 2011-07-28 | Monosol Rx, Llc | Orally administrable film dosage forms containing ondansetron |
| WO2012028922A2 (en) * | 2010-08-30 | 2012-03-08 | Lupin Limited | Controlled release pharmaceutical compositions of milnacipran |
| US20120128730A1 (en) | 2010-11-23 | 2012-05-24 | Nipun Davar | Compositions and methods for once-daily treatment of obsessive compulsive disorder with ondansetron |
| MX378261B (es) | 2013-03-14 | 2025-03-10 | Redhill Biopharma Ltd | Formas de dosificación sólidas de liberación prolongada antieméticas. |
-
2015
- 2015-03-11 SG SG11201607511WA patent/SG11201607511WA/en unknown
- 2015-03-11 JP JP2016556842A patent/JP6461186B2/ja active Active
- 2015-03-11 CA CA2941829A patent/CA2941829C/en active Active
- 2015-03-11 EP EP15761030.4A patent/EP3116500B1/en active Active
- 2015-03-11 MX MX2016011734A patent/MX373002B/es active IP Right Grant
- 2015-03-11 RU RU2016139474A patent/RU2706708C2/ru active
- 2015-03-11 WO PCT/IB2015/000997 patent/WO2015136377A2/en not_active Ceased
- 2015-03-11 KR KR1020167027738A patent/KR20160132057A/ko not_active Ceased
- 2015-03-11 UA UAA201610250A patent/UA121209C2/uk unknown
- 2015-03-11 BR BR112016020877-3A patent/BR112016020877B1/pt active IP Right Grant
- 2015-03-11 AU AU2015228545A patent/AU2015228545B2/en active Active
- 2015-03-11 CN CN201580024541.0A patent/CN106456611B/zh not_active Expired - Fee Related
- 2015-03-11 US US14/644,801 patent/US9675588B2/en active Active
-
2016
- 2016-09-06 CL CL2016002251A patent/CL2016002251A1/es unknown
- 2016-09-07 PH PH12016501756A patent/PH12016501756B1/en unknown
- 2016-09-08 IL IL247698A patent/IL247698B/en active IP Right Grant
- 2016-09-09 ZA ZA2016/06276A patent/ZA201606276B/en unknown
-
2017
- 2017-05-26 US US15/606,650 patent/US10668050B2/en active Active
-
2020
- 2020-04-29 US US16/861,752 patent/US20200253933A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016528302A5 (enExample) | ||
| CN103096881B (zh) | 含有具有不愉快味道的药物的膜制剂 | |
| JP5426018B2 (ja) | 易服用性固形製剤 | |
| JP2018527392A5 (enExample) | ||
| EA201071054A1 (ru) | Твердый препарат, растворяющийся во рту | |
| EA201892836A1 (ru) | Составы 2-[3-[4-амино-3-(2-фтор-4-феноксифенил)пиразол[3,4-d]пиримидин-1-ил]пиперидин-1-карбонил]-4-метил-4-[4-(оксетан-3-ил)пиперазин-1-ил]пент-2-еннитрила с модифицированным высвобождением | |
| JP2013508289A5 (enExample) | ||
| JP2015509519A5 (enExample) | ||
| JP2008280351A5 (enExample) | ||
| JP2016500088A5 (enExample) | ||
| RU2013141534A (ru) | Составы l-ментола, состоящие из множества частиц, и связанные с ними способы | |
| JP2015511635A5 (enExample) | ||
| JP2020510660A5 (enExample) | ||
| JP2015131825A5 (enExample) | ||
| RU2011152105A (ru) | Составы таблеток 3-цианохинолина и их применение | |
| JP2015510916A5 (enExample) | ||
| JP2019509345A5 (enExample) | ||
| RU2018111690A (ru) | Пероральная лекарственная форма будесонида | |
| JP2015508411A5 (enExample) | ||
| JP2016512493A5 (enExample) | ||
| JP2016516031A5 (enExample) | ||
| JP2013544795A5 (enExample) | ||
| RU2015150303A (ru) | Композиция, содержащая гидрокортизон | |
| WO2015136377A3 (en) | Ondansetron extended release solid dosage forms for treating either nausea, vomiting or diarrhea symptoms | |
| JP2016518439A5 (enExample) |